Real world cost of human epidermal receptor 2-positive metastatic breast cancer patients: a longitudinal incidence-based observational costing study in the Netherlands and Belgium

Metastatic breast cancer: We do need primary cost data

(2012) J. Bonastre et al.   BREAST

Cost-of-Illness Studies

(2011) Allison Larg et al.   PHARMACOECONOMICS

Trastuzumab beyond progression: a cost-utility analysis

(2010) K. W. Matter-Walstra et al.   ANNALS OF ONCOLOGY

The economics of improved cancer survival rates: better outcomes, higher costs

(2010) Carin A Uyl-de Groot et al.   Expert Review of Pharmacoeconomics & Outcomes Research

Treatment of Metastatic Breast Cancer

(2009) Bénédicte Poncet et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

The total hospital and community UK costs of managing patients with relapsed breast cancer

(2009) R J Thomas et al.   BRITISH JOURNAL OF CANCER

Health care costs for treatment of disseminated breast cancer

(2009) L. Dahlberg et al.   EUROPEAN JOURNAL OF CANCER

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

(2008) David Cameron et al.   BREAST CANCER RESEARCH AND TREATMENT

THE COST BURDEN OF TRASTUZUMAB AND BEVACIZUMAB THERAPY FOR SOLID TUMOURS IN CANADA

(2008) Arik Drucker   Current Oncology

Ten-Year Survival and Cost Following Breast Cancer Recurrence: Estimates from SEER-Medicare Data

(2007) Michael E. Stokes et al.   VALUE IN HEALTH